Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label phase 2 dose-comparison study of BL0175 in postmenopausal HR-positive/HER2-negative advanced or metastatic breast cancer
CTR20262347Phase 2Active
- Sponsor
- Biling Bio
- Start
- Sep 2026
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of BL0175 in breast cancer, sponsored by Biling Bio. Started Sep 2026; status: active.
02
Drugs
BL0175
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20262347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262347.